Ekaterina Alexeeva, Meiri Shingarova, Tatyana Dvoryakovskaya, Olga Lomakina, Anna Fetisova, Ksenia Isaeva, Aleksandra Chomakhidze, Kristina Chibisova, Elizaveta Krekhova, Aleksandra Kozodaeva, Kirill Savostyanov, Aleksandr Pushkov, Ilya Zhanin, Dmitry Demyanov, Evgeny Suspitsin, Konstantin Belozerov, Mikhail Kostik
INTRODUCTION: The blockade of interleukine-1 (anakinra and canakinumab) is a well-known highly effective tool for monogenic autoinflammatory diseases (AIDs), such as familial Mediterranean fever, tumor necrosis factor receptor-associated periodic syndrome, hyperimmunoglobulinaemia D syndrome, and cryopyrin-associated periodic syndrome, but this treatment has not been assessed for patients with undifferentiated AIDs (uAIDs). Our study aimed to assess the safety and efficacy of canakinumab for patients with uAIDs...
2023: Frontiers in Medicine